
## **Delvac Oceandy**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5383442/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effect of Angiotensin Converting Enzyme (ACE) I/D Polymorphism on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk in Non-Hemodialyzed Chronic Kidney Disease: The Mediating Role of Plasma ACE Level. Genes, 2022, 13, 1121.	1.0	3
2	Treatment with specific and pan-plasma membrane calcium ATPase (PMCA) inhibitors reduces malaria parasite growth in vitro and in vivo. Malaria Journal, 2022, 21, .	0.8	2
3	PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia. Scientific Reports, 2021, 11, 1518.	1.6	0
4	Cost-effectiveness of a mobile technology-enabled primary care intervention for cardiovascular disease risk management in rural Indonesia. Health Policy and Planning, 2021, 36, 435-443.	1.0	5
5	Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients. Human Genomics, 2021, 15, 29.	1.4	37
6	The plasma membrane calcium ATPase 4 does not influence parasite levels but partially promotes experimental cerebral malaria during murine blood stage malaria. Malaria Journal, 2021, 20, 297.	0.8	9
7	Stem cell therapy and diabetic erectile dysfunction: A critical review. World Journal of Stem Cells, 2021, 13, 1549-1563.	1.3	11
8	Signaling via the Interleukin-10 Receptor Attenuates Cardiac Hypertrophy in Mice During Pressure Overload, but not Isoproterenol Infusion. Frontiers in Pharmacology, 2020, 11, 559220.	1.6	15
9	Treatment with Mammalian Ste-20-like Kinase 1/2 (MST1/2) Inhibitor XMU-MP-1 Improves Glucose Tolerance in Streptozotocin-Induced Diabetes Mice. Molecules, 2020, 25, 4381.	1.7	14
10	Silencing miR-370-3p rescues funny current and sinus node function in heart failure. Scientific Reports, 2020, 10, 11279.	1.6	30
11	Enhancement of the Therapeutic Capacity of Mesenchymal Stem Cells by Genetic Modification: A Systematic Review. Frontiers in Cell and Developmental Biology, 2020, 8, 587776.	1.8	25
12	Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor <scp>XMUâ€MPâ€1,</scp> protects the heart against adverse effects during pressure overload. British Journal of Pharmacology, 2019, 176, 3956-3971.	2.7	67
13	The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways. International Journal of Molecular Sciences, 2019, 20, 2346.	1.8	20
14	Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth Extend study. PLoS ONE, 2019, 14, e0215219.	1.1	56
15	Cardiac hypertrophy or failure? - A systematic evaluation of the transverse aortic constriction model in C57BL/6NTac and C57BL/6J substrains. Current Research in Physiology, 2019, 1, 1-10.	0.8	22
16	Pak2 as a Novel Therapeutic Target for Cardioprotective Endoplasmic Reticulum Stress Response. Circulation Research, 2019, 124, 696-711.	2.0	48
17	201MAP1S ablation impairs survival after MI and the hypertrophic response to pressure overload through mediating cardiac autophagy and apoptosis. Cardiovascular Research, 2018, 114, S53-S53.	1.8	0
18	Genetic ablation of the mammalian sterile-20 like kinase 1 (Mst1) improves cell reprogramming efficiency and increases induced pluripotent stem cell proliferation and survival. Stem Cell Research, 2017, 20, 42-49.	0.3	12

DELVAC OCEANDY

#	Article	IF	CITATIONS
19	The Plasma Membrane Calcium ATP <scp>ases</scp> and Their Role as Major New Players in Human Disease. Physiological Reviews, 2017, 97, 1089-1125.	13.1	94
20	Targeting miR-423-5p Reverses Exercise Training–Induced HCN4 Channel Remodeling and Sinus Bradycardia. Circulation Research, 2017, 121, 1058-1068.	2.0	76
21	Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nature Communications, 2017, 8, 494.	5.8	59
22	Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide. FEBS Open Bio, 2017, 7, 1672-1685.	1.0	19
23	Selective inhibition of plasma membrane calcium ATPase 4 improves angiogenesis and vascular reperfusion. Journal of Molecular and Cellular Cardiology, 2017, 109, 38-47.	0.9	10
24	144â€Selective inhibition of plasma membrane calcium atpase 4 improves vegf-mediated angiogenesis. Heart, 2017, 103, A107.2-A107.	1.2	0
25	An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. Journal of Clinical Investigation, 2017, 127, 3065-3074.	3.9	48
26	One-Month Global Longitudinal Strain Identifies Patients Who Will Develop Pacing-Induced Left Ventricular Dysfunction over Time: The Pacing and Ventricular Dysfunction (PAVD) Study. PLoS ONE, 2017, 12, e0162072.	1.1	20
27	The Control of Sub-plasma Membrane Calcium Signalling by the Plasma Membrane Calcium ATPase Pump PMCA4. Cardiac and Vascular Biology, 2017, , 341-359.	0.2	0
28	The oxoglutarate receptor 1 (OXGR1) modulates pressure overload-induced cardiac hypertrophy in mice. Biochemical and Biophysical Research Communications, 2016, 479, 708-714.	1.0	20
29	The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy. Nature Communications, 2016, 7, 11074.	5.8	52
30	Plasma Membrane Calcium ATPase Isoform 4 Inhibits Vascular Endothelial Growth Factor–Mediated Angiogenesis Through Interaction With Calcineurin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2310-2320.	1.1	41
31	The tumour suppressor Ras-association domain family protein 1A (RASSF1A) regulates TNF-α signalling in cardiomyocytes. Cardiovascular Research, 2014, 103, 47-59.	1.8	10
32	The Mammalian Ste20-like Kinase 2 (Mst2) Modulates Stress-induced Cardiac Hypertrophy. Journal of Biological Chemistry, 2014, 289, 24275-24288.	1.6	26
33	Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases. Heart Failure Reviews, 2014, 19, 669-680.	1.7	11
34	Development and characterization of a novel fluorescent indicator protein PMCA4-GCaMP2 in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2013, 63, 57-68.	0.9	21
35	A Novel Immunomodulator, FTY-720 Reverses Existing Cardiac Hypertrophy and Fibrosis From Pressure Overload by Targeting NFAT (Nuclear Factor of Activated T-cells) Signaling and Periostin. Circulation: Heart Failure, 2013, 6, 833-844.	1.6	57
36	Optimisation and Validation of a High Throughput Screening Compatible Assay to Identify Inhibitors of the Plasma Membrane Calcium ATPase Pump - a Novel Therapeutic Target for Contraception and Malaria. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 217.	0.9	14

DELVAC OCEANDY

#	Article	IF	CITATIONS
37	Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. Carcinogenesis, 2012, 33, 2362-2368.	1.3	39
38	Local signals with global impacts and clinical implications: Lessons from the plasma membrane calcium pump (PMCA4). Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 974-978.	1.9	19
39	Calcium signaling dysfunction in heart disease. BioFactors, 2011, 37, 175-181.	2.6	12
40	Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps. Science China Life Sciences, 2011, 54, 691-698.	2.3	38
41	Plasma Membrane Calcium Pump (PMCA4)-Neuronal Nitric-oxide Synthase Complex Regulates Cardiac Contractility through Modulation of a Compartmentalized Cyclic Nucleotide Microdomain. Journal of Biological Chemistry, 2011, 286, 41520-41529.	1.6	69
42	Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. Cardiovascular Research, 2010, 87, 440-448.	1.8	46
43	Targeted Deletion of the Extracellular Signal-Regulated Protein Kinase 5 Attenuates Hypertrophic Response and Promotes Pressure Overload–Induced Apoptosis in the Heart. Circulation Research, 2010, 106, 961-970.	2.0	75
44	Measurement of Plasma Membrane Calcium–Calmodulin-Dependent ATPase (PMCA) Activity. Methods in Molecular Biology, 2010, 637, 333-342.	0.4	8
45	Cardiac-Specific Deletion of <i>Mkk4</i> Reveals Its Role in Pathological Hypertrophic Remodeling but Not in Physiological Cardiac Growth. Circulation Research, 2009, 104, 905-914.	2.0	67
46	Specific Role of Neuronal Nitric-oxide Synthase when Tethered to the Plasma Membrane Calcium Pump in Regulating the β-Adrenergic Signal in the Myocardium. Journal of Biological Chemistry, 2009, 284, 12091-12098.	1.6	34
47	Tumor Suppressor Ras-Association Domain Family 1 Isoform A Is a Novel Regulator of Cardiac Hypertrophy. Circulation, 2009, 120, 607-616.	1.6	60
48	Ras-Association Domain Family Member 1A (RASSF1A)—Where the Heart and Cancer Meet. Trends in Cardiovascular Medicine, 2009, 19, 262-267.	2.3	7
49	Physiological implications of the interaction between the plasma membrane calcium pump and nNOS. Pflugers Archiv European Journal of Physiology, 2009, 457, 665-671.	1.3	31
50	Neuronal Nitric Oxide Synthase Signaling in the Heart Is Regulated by the Sarcolemmal Calcium Pump 4b. Circulation, 2007, 115, 483-492.	1.6	99
51	The regulatory function of plasma-membrane Ca2+-ATPase (PMCA) in the heart. Biochemical Society Transactions, 2007, 35, 927-930.	1.6	35
52	Targeting the Sarcolemmal Calcium Pump: A Potential Novel Strategy for the Treatment of Cardiovascular Disease. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 300-304.	0.4	3
53	Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodelling in mitral valve prolapse patients. European Journal of Heart Failure, 2007, 9, 1010-1017.	2.9	15
54	Plasma Membrane Calcium ATPase and Its Relationship to Nitric Oxide Signaling in the Heart. Annals of the New York Academy of Sciences, 2007, 1099, 247-253.	1.8	17

DELVAC OCEANDY

#	Article	IF	CITATIONS
55	The Emergence of Plasma Membrane Calcium Pump as a Novel Therapeutic Target for Heart Disease. Mini-Reviews in Medicinal Chemistry, 2006, 6, 583-588.	1.1	11
56	The Sarcolemmal Calcium Pump, α-1 Syntrophin, and Neuronal Nitric-oxide Synthase Are Parts of a Macromolecular Protein Complex. Journal of Biological Chemistry, 2006, 281, 23341-23348.	1.6	127
57	The Sarcolemmal Calcium Pump Inhibits the Calcineurin/Nuclear Factor of Activated T-cell Pathway via Interaction with the Calcineurin A Catalytic Subunit. Journal of Biological Chemistry, 2005, 280, 29479-29487.	1.6	81
58	Novel Functional Interaction between the Plasma Membrane Ca2+ Pump 4b and the Proapoptotic Tumor Suppressor Ras-associated Factor 1 (RASSF1). Journal of Biological Chemistry, 2004, 279, 31318-31328.	1.6	92
59	Plasma Membrane Ca2+ ATPase 4 Is Required for Sperm Motility and Male Fertility. Journal of Biological Chemistry, 2004, 279, 28220-28226.	1.6	213
60	GFP-tagged CFTR transgene is functional in the G551D cystic fibrosis mouse colon. Journal of Membrane Biology, 2003, 192, 159-167.	1.0	10
61	A macrophage colony-stimulating factor receptor–green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood, 2003, 101, 1155-1163.	0.6	605
62	Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Human Molecular Genetics, 2002, 11, 1059-1067.	1.4	50